Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Why $SMMT’s PD-1/VEGF bispecific is no longer just a drug story—and how its FDA review could redraw the path from Chinese discovery to global oncology markets, with $MRK’s Keytruda franchise directly in view.
Two damaged regulatory stories return to the same FDA advisory committee on consecutive days. Capricor brings a new randomized Phase 3 dataset in Duchenne muscular dystrophy; Replimune asks the agency to reconsider accelerated approval after two Complete Response Letters in advanced melanoma. This report separates the clinical evidence, the likely pressure points, the retail narrative and the decisions that actually matter.
The July 20–24 tape punished Alphabet and Tesla, pushed Brent above $100 before a late retreat, and kept rotation alive below the mega-cap surface. Next comes the Federal Reserve, GDP, PCE, Microsoft, Meta, Apple, Amazon and back-to-back FDA Advisory Committee meetings.
Golden Dome is no longer only a presidential vision or a broad market narrative. Congress has begun writing oversight into law, billions are moving through missile-warning and tracking awards, and the next political battle is already forming around FY2027 funding, space-based interceptors, acquisition authority and the true cost of defending the U.S. homeland.
A complete cannabis-sector update: the federal hearing is over, but a decision is not imminent; Congress is split between legalization and an attempt to block rescheduling; industry political donations are rising; and a parallel court fight could delay the process. Meanwhile, Aurora Cannabis, Tilray Brands, Cronos Group and Canopy Growth are looking for company-specific catalysts that do not depend entirely on Washington.
Six verified biotech developments published today: an accepted rare-disease NDA, updated PCNSL response data, the opening of a rolling Wilson-disease application, a positive brain-metastases imaging study, a Canadian ALS regulatory path and a $1.5 billion cell-therapy tools acquisition.
A framework for reading the critical-minerals sector: why the real bottleneck is processing (the midstream), a four-question tool to triage any headline, with $UAMY as the worked example and $MP, $USAR and $TMC on the map.
How Rare Pediatric Disease Priority Review Vouchers turn a single FDA approval into $180-205 million in non-dilutive cash - the mechanism explained, with $RCKT and $DNLI as worked examples.
Kalshi launched a pilot program on July 16, 2026, enabling trading on clinical trial outcomes and FDA decisions linked to biotech firms. This new prediction market offers a public price reflecting the probability of drug approval, but raises ethical concerns and potential manipulation risks due to limited participant knowledge and liquidity challenges.
Congress stripped the provision that would have defunded marijuana rescheduling — the House passed the clean bill 397-28 — and cannabis investors never priced it. Meanwhile the sector fell during the DEA hearing itself.
Three small- and mid-cap biotechnology companies are chasing the same strategic prize—durable retinal-disease control with fewer injections—but they are using different technologies, different delivery routes and radically different levels of clinical evidence.
Insider trading this week (July 13-17, 2026): the 20 biggest open-market buys and 20 biggest executed sells by dollar value, with names, tickers, amounts and next catalysts. Educational, not advice.
The July 13–17 tape delivered a sharp semiconductor reset, cooler inflation data, a renewed oil shock and resilient rotation below the headline indices. Next comes Alphabet, Tesla, Texas Instruments and Intel, plus AMD’s AI event, Farnborough, biotech data and a weekend FDA decision.
A full three-company edition covering an early wet-AMD durability signal, a $100 million gene-therapy financing that materially resets per-share ownership, and a traditional FDA approval that raises the evidence standard across the increasingly competitive IgA-nephropathy market.
A U.S.-only defense report covering traditional primes, scaled defense-tech, high-beta drone and AI names, and national-security space companies already followed by Merlintrader. The central question is not whether military demand exists, but which companies can turn budgets and contract ceilings into funded backlog, margins and free cash flow per share.
The space economy has not stopped growing, but its public-market proxies have lost scarcity, absorbed a wave of new securities and broken key technical support. This report separates the common sector shock from each company’s own risks and identifies what would have to change before the decline can credibly reverse.
Jasper has acquired Kira Pharmaceuticals and preserved its Nasdaq ticker, but the company behind that ticker is being rebuilt around Kira’s complement pipeline. The financing solves an immediate liquidity crisis; the ownership math leaves legacy Jasper holders with only 6.68% of the combined company and creates a capital structure that will almost certainly require further corporate action.
How the HALEU enrichment bottleneck decides the advanced-reactor race: the fuel-cycle map, a reusable triage tool, and $OKLO, $LEU and $CCJ as worked examples.
Three biotech updates, three very different evidence problems: an early Parkinson’s disease signal moving toward Phase 2, a post hoc attempt to rescue a pulmonary sarcoidosis program after a missed Phase 3 endpoint, and an FDA-guided protocol optimization that may make a urology study faster and less expensive without yet proving efficacy.
The AI boom is no longer only a semiconductor and cloud-computing story. It is becoming a race for mission-ready software, deployable electricity and secure magnet supply. This report separates the common narrative from the very different financial realities of BigBear.ai, Bloom Energy and MP Materials.